[DOI] [PMC free article] [PubMed] [Google Scholar] 150.Gonzalez V.H., Campbell J., Holekamp N.M., Kiss S., Loewenstein A., Augustin A.J., Ma J., Ho A.C., Patel V., Whitcup S.M., et al
General considerations when you are deciding whether GLP-1 agonists or tirzepatide are right for you: GLP-1 agonists increase hormones called incretins
General subcutaneous injection at distant sites like the abdomen can still provide systemic benefits, just potentially with a slower onset for the specific shoulder condition
217221 Therefore, pharmacokinetic changes in drugs mediated by increased GFR and renal plasma flow following GLP-1 RA administration may occur, and the impact of its mechanism of action need to be investigated in the future